Johnson & Johnson's Q3 2023: $21.3B Rise In Sales, 'Sharpened Focus' On Innovation & Biotech Solutions
Johnson & Johnson's Q3 2023: $21.3B Rise In Sales, 'Sharpened Focus' On Innovation & Biotech Solutions
Healthcare company Johnson & Johnson (J&J) (NYSE:JNJ) shared its financial outcomes for the third quarter of 2023, reflecting:
醫療保健公司 強生（強生） 紐約證券交易所代碼：JNJ）分享了其財務業績 2023 年第三季度， 反映：
-
Total reported sales of $21,351 million, a 6.8% increase compared to the same period in 2022. Of which U.S. sales totaled $11,996 million (11.1% increase from 2022's comparable period), and the rest of the world $9,355 million (1.6% increase from 2022's same period.)
-
In terms of segments, reported sales owe 65.0% to Innovate Medicine ($13,893 million, a 5.1% growth from 2022's same period); and 34.9% to MedTech ($7,458 million, a 10.0% growth from 2022's same period.)
-
In terms of psychedelics, these numbers involve Spratavo (S-ketamine) sales for a total of $154 million in the U.S., a 75% increase compared to 2022's same quarter and $29 million in the rest of the world.
-
報告的銷售總額 在213.51億美元中，a 增長 6.8% 與2022年同期相比。其中 美國的銷售總額爲119.96億美元 （比2022年同期增長11.1％），世界其他地區爲93.55億美元（比2022年同期增長1.6％）。
-
就細分市場而言，已報告 銷售額欠創新醫學65.0％ （138.93億美元，比2022年同期增長5.1％）； 34.9% 流向醫療科技 （74.58億美元，比2022年同期增長10.0％。）
-
在迷幻藥方面，這些數字涉及 Spratavo（s-ketamine）的銷量 在美國的總收入爲1.54億美元，與2022年同期相比增長了75％，在世界其他地區增長了2900萬美元。
See Also: Sales Of Johnson & Johnson Esketamine Drug Spravato Rise Nearly 100% Year Over Year
另見：強生公司埃西胺酮藥物 Spravato 的銷量同比增長近 100%
-
Net earnings of $4,309 million, slightly behind 2022's comparable period of $4,310 million. Yet earnings per share (diluted) increased 4.3% from period to period from $1.62 in 2022 to $1.69 in 2023.
-
The cost of products sold was $6,606 million vs. $6,172 million in the same 2022 period.
-
R&D expenses totaled $3,447 million, vs. $3,485 million in the same 2022 period.
-
Selling, marketing and administrative expenses for a total $5,400 million, an 8% increase from 2022 ($4,975 million.)
-
淨收益爲43.09億美元，略低於2022年同期的43.1億美元。然而，每股收益（攤薄）同比增長4.3％，從2022年的1.62美元增至2023年的1.69美元。
-
所售產品的成本 爲66.06億美元，而2022年同期爲61.72億美元。
-
研發費用 總額爲34.47億美元，而2022年同期爲34.85億美元。
-
銷售、營銷和管理費用總額爲54億美元，比2022年（49.75億美元）增長8％。
The quarter also saw a one-time, non-cash gain of around $21 billion, related to the final separation of J&J's consumer health business and considered as part of its discontinued operations.
本季度還出現了 一次性非現金收益約爲210億美元，與強生消費者健康業務的最終分離有關，被視爲其已終止業務的一部分。
Pipeline, Programs & IP
管道、項目和知識產權
On the regulatory front, J&J received several treatment approvals from the FDA and the European Commission (2). Additionally, it submitted two applications to the European Medicines Agency, and another supplemental New Drug Application (NDA) to the FDA.
在 監管方面，強生獲得了多項治療批准 食品藥品管理局 和 歐盟委員會 (2)。此外，它還向該委員會提交了兩份申請 歐洲藥品管理局，以及美國食品和藥物管理局的另一項補充新藥申請（NDA）。
The company also released data on several different development programs, around the multi-targeting bispecific monoclonal antibody RYBREVANT. It as launched the OPTRELL catheter for the mapping of complex cardiac arrhythmias.
該公司還發布了圍繞多靶向雙特異性單克隆抗體RYBREVANT的幾個不同開發項目的數據。它剛剛推出 OPTRELL 導管 用於繪製複雜心律失常的地圖。
CEO and board chairman Joaquin Duato said the quarter's "strong results" along with "significant pipeline advances" altogether provide "a solid foundation for future sustained growth."
首席執行官兼董事會主席華金·杜阿託 表示，本季度的 “強勁業績” 以及 “重大產品線進展” 爲 “未來的持續增長奠定了堅實的基礎”。
"With a sharpened focus on Innovative Medicine and MedTech solutions, Johnson & Johnson is innovating across the spectrum of healthcare and is poised to deliver the medical breakthroughs of tomorrow," Duato added.
杜阿託補充說：“強生公司更加關注創新醫學和醫療技術解決方案，正在醫療保健領域進行創新，並有望實現未來的醫學突破。”
See full financial results, business collaborations and earnings presentation here.
在此處查看完整的財務業績、業務合作和收益報告。
Photo: Benzinga edit with photo by Commons and Pexels.
照片：Benzinga 編輯，照片由 Commons 和 Pexels 拍攝。
譯文內容由第三人軟體翻譯。